|
生物種
|
リソース名
|
RRC ID
|
タイトル
|
ジャーナル
|
公開日
|
外部リンク
|
|
ヒト・動物細胞
|
RBE(RCB1292)
|
79009
|
EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
|
Cancer Discov |
2022-5-2 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
HuCCT1(RCB1960)
,
RBE(RCB1292)
,
SSP-25(RCB1293)
,
HuH-28(RCB1943)
|
66894
|
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
|
Cancer Discov |
2019-8-1 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
MC3T3-G2/PA6(RCB1127)
|
63719
|
Inhibition of FGF10-ERK signal activation suppresses intraductal papillary neoplasm of the bile duct and its associated carcinomas.
|
Cell Rep |
2021-2-23 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
10T1/2(RCB0247)
|
62002
|
Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3.
|
Sci Rep |
2018-9-10 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
JHUEM-2(RCB1551)
|
54768
|
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
|
Mol Oncol |
2019-4-1 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
GCIY(RCB0555)
,
ECC12(RCB1009)
,
KE-97(RCB1435)
|
44956
|
Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
|
Cancer Sci |
2014-5-1 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
OP9(RCB1124)
|
44656
|
FGF7 supports hematopoietic stem and progenitor cells and niche-dependent myeloblastoma cells via autocrine action on bone marrow stromal cells in vitro.
|
Biochem Biophys Res Commun |
2013-10-11 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
JHUEM-2(RCB1551)
|
44564
|
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
|
Neoplasia |
2013-8-1 |
Pubmed
Full text
|
|
ヒト・動物細胞
|
KATO-III
,
MKN-1
,
MKN-7
,
MKN-45
,
MKN-74
|
38545
|
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
|
Invest New Drugs |
2012-8-1 |
Pubmed
Full text
|